Mereo BioPharma
Mereo BioPharma

Financials • Mereo BioPharma

MREO

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2016
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2017
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2018
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2019
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2020
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
12/2021
49
-27
01
35%
0.15
119
14%
-108
-
-12
-1
105
-12
0
0
-
-
12/2022
0
-52
-12
0%
L
76
L
-68
-
-52
-0
-1
-52
0
0
-
-
12/2023
10
-27
-12
L
L
63
L
-52
-
-28
-0
6
-28
0
0
-
-
12/2024
0
-46
-12
0%
L
61
L
-70
-
-40
-1
46
-41
0
0
-
-
12/2025
1
-39
-12
L
L
41
L
-41
-
-39
-0
0
-39
0
0
-
-

To see all financials—including updated, you must be Premium.